Menopause and risk of hip fracture in middle-aged Chinese women: a 10-year follow-up of China Kadoorie Biobank.


Journal

Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353

Informations de publication

Date de publication:
03 2020
Historique:
pubmed: 27 12 2019
medline: 5 1 2021
entrez: 27 12 2019
Statut: ppublish

Résumé

Bone loss is accelerated after menopause in women, as is the risk of hip fracture, but little is known about the importance of age at menopause, time since menopause, and total reproductive years for risk of hip fracture. Between 2004 and 2008, the China Kadoorie Biobank recruited 125,336 postmenopausal women who had a natural menopause and recorded 1,327 incident cases of hip fracture during the first 10 years of follow-up. Multivariable Cox regression was used to estimate hazard ratios and 95% CIs for incident hip fracture for age at menopause, time since menopause, and total reproductive years. The mean (SD) age at menopause was 48.8 (4.0) years. Compared with women who reached menopause before age 53 years, women with a later age at menopause had a 22% (95% CI, 11%-35%) lower risk of hip fracture. Compared with women who were <5 years since menopause, those who were 5 to 9, 10 to 14, 15 to 19, and ≥20 years since menopause had hazard ratios of hip fracture of 1.43 (95% CI, 1.01-2.04), 2.10 (95% CI, 1.71-2.57), 2.50 (95% CI, 2.21-2.83), and 2.33 (95% CI, 1.97-2.75), respectively. Women with a longer (≥36 y) versus shorter (<30 y) duration of total reproductive years had a 19% (95% CI, 9-28) lower risk of hip fracture. Women with younger age at menopause, longer interval since menopause, or shorter duration of total reproductive years had the highest risks of hip fracture.

Identifiants

pubmed: 31876618
doi: 10.1097/GME.0000000000001478
pii: 00042192-202003000-00010
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

311-318

Subventions

Organisme : Wellcome Trust
ID : 212946/Z/18/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 29186
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12026/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00017/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U137686851
Pays : United Kingdom

Références

Johnell O, Kanis J. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004; 15:897–902.
Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003; 51:364–370.
Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997; 45:281–287.
Farahmand BY, Michaelsson K, Ahlbom A, et al. Survival after hip fracture. Osteoporos Int 2005; 16:1583–1590.
Xia WB, He SL, Xu L, et al. Rapidly increasing rates of hip fracture in Beijing, China. J Bone Mineral Res 2012; 27:125–129.
Li S, Sun T, Liu Z. Excess mortality of 1 year in elderly hip fracture patients compared with the general population in Beijing, China. Arch Osteoporos 2016; 11:35.
Tian M, Gong X, Rath S, et al. Management of hip fractures in older people in Beijing: a retrospective audit and comparison with evidence-based guidelines and practice in the UK. Osteoporos Int 2016; 27:677–681.
Hopkins R, Pullenayegum E, Goeree R, et al. Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int 2012; 23:921–927.
Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149:2445–2448.
Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995; 43:1214–1221.
Ambrose AF, Paul G, Hausdorff JM. Risk factors for falls among older adults: a review of the literature. Maturitas 2013; 75:51–61.
Samelson EJ, Hannan MT. Epidemiology of osteoporosis. Curr Rheumatol Rep 2006; 8:76–83.
Morcov C, Vulpoi C, Brănişteanu D. Relationship between bone mineral density, weight, and estrogen levels in pre and postmenopausal women. Rev Med Chir Soc Med Nat Iasi 2012; 116:946–950.
Ho-Pham LT, Nguyen ND, Nguyen TV. Quantification of the relative contribution of estrogen to bone mineral density in men and women. BMC Musculoskelet Disord 2013; 14:366.
Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13:763–773.
Chew CK, Clarke BL. Causes of low peak bone mass in women. Maturitas 2018; 111:61–68.
Sasson H, Carpenter C. Achievement of peak bone mass in women is critically dependent on adolescent calcium intake. OA Sports Med 2013; 1:16.
Dasarathy J, Labrador H. Bone health in women. Primary Care 2018; 45:643–657.
Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986; 314:1676–1686.
Sirola J, Kröger H, Honkanen R, et al. Factors affecting bone loss around menopause in women without HRT: a prospective study. Maturitas 2003; 45:159–167.
Ahlborg H, Johnell O, Nilsson B, et al. Bone loss in relation to menopause: a prospective study during 16 years. Bone 2001; 28:327–331.
Recker R, Lappe J, Davies K, et al. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res 2000; 15:1965–1973.
Sowers MR, Zheng H, Jannausch ML, et al. Amount of bone loss in relation to time around the final menstrual period and follicle-stimulating hormone staging of the transmenopause. J Clin Endocrinol Metab 2010; 95:2155–2162.
Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93:861–868.
Compston JE. HRT and osteoporosis. Br Med Bull 1992; 48:309–344.
Cummings SR, Kelsey JL, Nevitt MC, et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev 1985; 7:178–208.
Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med 1998; 339:733–738.
Cumming RG, Klineberg RJ. Breastfeeding and other reproductive factors and the risk of hip fractures in elderly women. Int J Epidemiol 1993; 22:684–691.
Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011; 40:1652–1666.
Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 1991; 10:1025–1035.
Banks E, Reeves GK, Beral V, et al. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLoS Med 2009; 6:e1000181.
Chen F-P, Hsu K-H, Fu T-S, et al. Risk factor for first-incident hip fracture in Taiwanese postmenopausal women. Taiwanese J Obstet Gynecol 2016; 55:258–262.
Parazzini F, Tavani A, Ricci E, et al. Menstrual and reproductive factors and hip fractures in post menopausal women. Maturitas 1996; 24:191–196.
Huo D, Lauderdale DS, Li L. Influence of reproductive factors on hip fracture risk in Chinese women. Osteoporos Int 2003; 14:694–700.
Wark JD. Osteoporotic fractures: background and prevention strategies. Maturitas 1996; 23:193–207.
Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:795–841.
Kang H, Chen YM, Han G, et al. Associations of age, BMI, and years of menstruation with proximal femur strength in Chinese postmenopausal women: a cross-sectional study. Int J Environ Res Public Health 2016; 13:157.
Jacobsen BK, Nilssen S, Heuch I, et al. Reproductive factors and fatal hip fractures. A Norwegian prospective study of 63,000 women. J Epidemiol Community Health 1998; 52:645–650.

Auteurs

Ke Peng (K)

School of Public Health, The University of Sydney, Sydney, Australia.
The George Institute for Global Health, UNSW, Sydney, Australia.
Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Pang Yao (P)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Christiana Kartsonaki (C)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Ling Yang (L)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Derrick Bennett (D)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Maoyi Tian (M)

The George Institute for Global Health, UNSW, Sydney, Australia.
The George Institute for Global Health at Peking University Health Science Center, Beijing, China.

Liming Li (L)

Chinese Academy of Medical Sciences, Beijing, China.

Yu Guo (Y)

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.

Zheng Bian (Z)

Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.

Yiping Chen (Y)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Zhengming Chen (Z)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Rebecca Ivers (R)

School of Public Health, The University of Sydney, Sydney, Australia.
The George Institute for Global Health, UNSW, Sydney, Australia.
School of Public Health and Community Medicine, UNSW, Sydney, Australia.

Mark Woodward (M)

The George Institute for Global Health, UNSW, Sydney, Australia.
The George Institute for Global Health, Oxford University, Oxford, United Kingdom.
Department of Epidemiology, Johns Hopkins University, Baltimore, MD.

Robert Clarke (R)

Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Old Road Campus, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH